Connect with us

Women's health

US research programme studies cannabinoids in ovarian cancer

Pebble Life Sciences has partnered with a leading US cancer research centre to carry out its studies.

Published

on

Pebble Life Sciences, a Texas-based cannabinoid company has partnered with a leading US cancer research centre
Pebble Life Sciences have been studying the role of multi-cannabinoid formulations in the disease since 2020.

Estimated reading time: 2 minutes

A US-based research programme is exploring the effects of cannabinoids in ovarian cancer.

Pebble Life Sciences, a Texas-based cannabinoid company has partnered with a leading US cancer research centre to evaluate how cannabinoid formulations could be used as potential treatment for ovarian cancer.

Despite being one of the most researched, ovarian cancer is the leading cause of gynaecological cancer in the US and second most globally.

In the UK, around 7,500 women are diagnosed with ovarian cancer each year. If diagnosed early, nine in 10 will survive, but two thirds of women are diagnosed late, when the cancer is harder to treat.

It is the fifth leading cause of cancer death in US women, with 22,000 diagnosed in 2021, resulting in 14,000 deaths.

US research programme studies cannabinoids in ovarian cancer

Pebble Life Sciences have been studying the role of multi-cannabinoid formulations in the disease since 2020, in partnership with the world leading MD Anderson Cancer Center (MDACC), which is devoted exclusively to cancer patient care, education, prevention, research.

Pebble’s Research Foundation has previously studied the role of cannabinoids in neurological disorders and other forms of cancer.

Using data from case studies, MDACC put a Pebble prototype formulation to the test in-vitro (petri dish) and then in-vivo (mice). Two years into the process, those proof-of-concept studies are said to have provided promising results.

Pebble is the only pharmaceutical grade, GMPc manufactured, and cannabinoid-based product available over the counter in the US.

The company has now revealed that it plans to continue its work with MDACC.

Pebble Founder and CEO, Patrick Moran, says he hopes the fact that its formulations don’t contain any THC, will allow them to help more women across the globe.

Moran commented: “Our team has thoroughly enjoyed working with MD Anderson the past two years on this novel therapy. We’re excited to continue with MD Anderson, to improve cancer treatment standards of care.

“Pebble’s non-THC, non-psychotropic approach permits a regulatory drug pathway that allows both domestic and global distribution, so we can help as many suffering women as possible.”

Home » Health » Women’s health » US research programme studies cannabinoids in ovarian cancer

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.